Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Anti-Counterfeiting Public Meeting To Display Current Technology

Executive Summary

FDA's public meeting on drug counterfeiting Oct. 15 will feature vendor displays of current anti-counterfeiting technology

You may also be interested in...



FDA Anti-Counterfeit Technology Policy Head Is Ex-CMS Staffer Rudolf

FDA's development of a policy on technology-based anti-counterfeiting efforts will be overseen by Senior Advisor for Medical & Health Policy Paul Rudolf, MD

FDA Anti-Counterfeit Technology Policy Head Is Ex-CMS Staffer Rudolf

FDA's development of a policy on technology-based anti-counterfeiting efforts will be overseen by Senior Advisor for Medical & Health Policy Paul Rudolf, MD

FDA Counterfeit Report Seeks “Electronic Pedigree” To Aid Drug Tracking

The pharmaceutical industry's long-term goal in counterfeit prevention should be to have all drug products contain an "electronic pedigree," FDA's Counterfeit Drug Task Force interim report says

Related Content

UsernamePublicRestriction

Register

LL1129367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel